Recombinant Human Integrin alpha V beta 3 Protein, CF | R&D Systems 3050-AV-050 product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human Integrin alpha V beta 3 Protein, CF

catalog :

3050-AV-050

quantity :

50 ug

price :

468 USD

more info or order :

R&D Systems product webpage

citations: 25

Reference
Josefsson A, Cortez A, Yu J, Majumdar S, Bhise A, Hobbs R, et al. Evaluation of targeting αVβ3 in breast cancers using RGD peptide-based agents. Nucl Med Biol. 2024;128-129:108880 pubmed publisher
Kim H, Jeong S, Park M, Bhosale P, Abusaliya A, Kim H, et al. Potential Joint Protective and Anti-Inflammatory Effects of Integrin αvβ3 in IL-1β-Treated Chondrocytes Cells. Biomedicines. 2023;11: pubmed publisher
Gerwin N, Scotti C, Halleux C, Fornaro M, Elliott J, Zhang Y, et al. Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. Nat Med. 2022;28:2633-2645 pubmed publisher
Yagolovich A, Isakova A, Artykov A, Vorontsova Y, Mazur D, Antipova N, et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int J Mol Sci. 2022;23: pubmed publisher
Nader D, Kerrigan S. Molecular Cross-Talk between Integrins and Cadherins Leads to a Loss of Vascular Barrier Integrity during SARS-CoV-2 Infection. Viruses. 2022;14: pubmed publisher
Bugatti A, Filippini F, Bardelli M, Zani A, Chiodelli P, Messali S, et al. SARS-CoV-2 Infects Human ACE2-Negative Endothelial Cells through an αvβ3 Integrin-Mediated Endocytosis Even in the Presence of Vaccine-Elicited Neutralizing Antibodies. Viruses. 2022;14: pubmed publisher
Norris E, Pan X, Hocking D. Receptor binding domain of SARS-CoV-2 is a functional αv-integrin agonist. bioRxiv. 2022;: pubmed publisher
Bieri M, Hendrickx R, Bauer M, Yu B, Jetzer T, Dreier B, et al. The RGD-binding integrins αvβ6 and αvβ8 are receptors for mouse adenovirus-1 and -3 infection. PLoS Pathog. 2021;17:e1010083 pubmed publisher
Agarwal S, Koh K, Tardi N, Chen C, Dande R, WerneckdeCastro J, et al. Deiodinase-3 is a thyrostat to regulate podocyte homeostasis. EBioMedicine. 2021;72:103617 pubmed publisher
Fnu G, Agrawal P, Kundu G, Weber G. Structural Constraint of Osteopontin Facilitates Efficient Binding to CD44. Biomolecules. 2021;11: pubmed publisher
Peng L, Wang M, Chu Y, Zhang L, Niu J, Shao H, et al. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma. Sci Adv. 2020;6:eaba2735 pubmed publisher
Szlachcic A, Sochacka M, Czyrek A, Opaliński L, Krowarsch D, Otlewski J, et al. Low Stability of Integrin-Binding Deficient Mutant of FGF1 Restricts Its Biological Activity. Cells. 2019;8: pubmed publisher
Bhatnagar S, Khera E, Liao J, Eniola V, Hu Y, Smith D, et al. Oral and Subcutaneous Administration of a Near-Infrared Fluorescent Molecular Imaging Agent Detects Inflammation in a Mouse Model of Rheumatoid Arthritis. Sci Rep. 2019;9:4661 pubmed publisher
Koh K, Cao Y, Mangos S, Tardi N, Dande R, Lee H, et al. Nonimmune cell-derived ICOS ligand functions as a renoprotective αvβ3 integrin-selective antagonist. J Clin Invest. 2019;129:1713-1726 pubmed publisher
Székács I, Farkas E, Gemes B, Takács E, Székács A, Horvath R. Integrin targeting of glyphosate and its cell adhesion modulation effects on osteoblastic MC3T3-E1 cells revealed by label-free optical biosensing. Sci Rep. 2018;8:17401 pubmed publisher
Zur Y, Rosenfeld L, Keshelman C, Dalal N, Guterman Ram G, Orenbuch A, et al. A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and αvβ3 integrin for osteoporosis therapy. PLoS Biol. 2018;16:e2002979 pubmed publisher
Barbhuiya M, Mirando A, Simons B, Lemtiri Chlieh G, Green J, Popel A, et al. Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. Oncotarget. 2017;8:101520-101534 pubmed publisher
Hedhli J, Czerwinski A, Schuelke M, Płoska A, Sowiński P, Hood L, et al. Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of α V β 3 Integrin Activity. Sci Rep. 2017;7:3185 pubmed publisher
Whilding L, Parente Pereira A, Zabinski T, Davies D, Petrovic R, Kao Y, et al. Targeting of Aberrant Î±vÎ²6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. Mol Ther. 2017;25:259-273 pubmed publisher
Brown A, Dysart M, Clarke K, STABENFELDT S, Barker T. Integrin Î±3Î²1 Binding to Fibronectin Is Dependent on the Ninth Type III Repeat. J Biol Chem. 2015;290:25534-47 pubmed publisher
Hussain S, Rodriguez Fernandez M, Braun G, Doyle F, Ruoslahti E. Quantity and accessibility for specific targeting of receptors in tumours. Sci Rep. 2014;4:5232 pubmed publisher
Lung H, Man O, Yeung M, Ko J, Cheung A, Law E, et al. SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma. Oncogene. 2015;34:878-89 pubmed publisher
Kwon I, Hong S, Kim Y, Nam H, Kang S, Yang S, et al. Thrombolytic effects of the snake venom disintegrin saxatilin determined by novel assessment methods: a FeCl3-induced thrombosis model in mice. PLoS ONE. 2013;8:e81165 pubmed publisher
Shojaei F, Scott N, Kang X, Lappin P, Fitzgerald A, Karlicek S, et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res. 2012;31:26 pubmed publisher
Jullienne B, Vigant F, Muth E, Chaligne R, Bouquet C, Giraudier S, et al. Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther. 2009;16:1405-15 pubmed publisher

product information

master code :

3050-AV

SKU :

3050-AV-050

product name :

Recombinant Human Integrin alpha V beta 3 Protein, CF

unit size :

50 ug

description :

The Recombinant Human Integrin alpha V beta 3 Protein, CF from R&D Systems is derived from CHO. The Recombinant Human Integrin alpha V beta 3 Protein, CF has been validated for the following applications: Binding Activity.

target :

Integrin alpha V beta 3

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in Tris, NaCl and CaCl2.

conjugate :

Unconjugated

purity :

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

species :

Human

observed molecular weight :

105-150 kDa, reducing conditions

theoretical molecular weight :

110.5 kDa ( alpha V subunit), 80.8 kDa (▀3 subunit)

gene symbol :

ITGAV

details of functionality :

Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human Vitronectin (Catalog # 2308-VN ) at 1 ╡g/mL can bind Recombinant Human Integrin alpha V▀3 with an apparent KD 10 nM.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

NP_002201 (Integrin alpha V) AAA52589 (Integrin ▀3)

applications :

Binding Activity

source long :

Chinese Hamster Ovary cell line, CHO-derived human Integrin alpha V beta 3 protein Human Integrin alpha V subunit (Phe31-Val992) Accession # NP_002201 His-Pro GGGSGGGS Acidic Tail Human Integrin ▀3 subunit (Gly27-Asp718) Accession # AAA52589 His-Pro GGGSGGGS Basic Tail N-terminus C-terminus

source short :

CHO

USD :

468 USD

alt names :

antigen identified by monoclonal L230, CD51, CD51 antigen, integrin alpha-V, integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51), MSK8, Vitronectin receptor subunit alpha, VNRADKFZp686A08142

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage